Generated by Rank Math SEO, this is an llms.txt file designed to help LLMs better understand and index this website.

# medmira

## Sitemaps
[XML Sitemap](https://medmira.com/sitemap_index.xml): Includes all crawlable and indexable pages.

## Posts
- [Health Canada approves MedMira’s Reveal® Rapid TP Test – Urgent New Tool In The Battle Against Syphilis](https://medmira.com/press-release/health-canada-approves-medmiras-reveal-rapid-tp-test-urgent-new-tool-in-the-battle-against-syphilis/): Halifax, Nova Scotia, 26 August 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received approval from Health Canada for its Reveal® TP (Syphilis) Antibody Test (Reveal® TP) – the fastest standalone screening device for syphilis in Canada. A vital point-of-care tool for healthcare professionals, Reveal® TP is a crucial advancement in expanding access to syphilis testing across Canada—particularly in the Prairie provinces, where rates of infectious and congenital syphilis are surging.
- [MedMira Announces Launch of Clinical Trial for Its Multiplo® TP/HIV Self-Test in Canada](https://medmira.com/press-release/medmira-announces-launch-of-clinical-trial-for-its-multiplo-tp-hiv-self-test-in-canada/): Halifax, Nova Scotia, July 16, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) and REACH Nexus are excited to announce a clinical trial has officially started earlier than anticipated to evaluate MedMira’s Multiplo® TP/HIV rapid test for use as a self-test in Canada.
- [MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal® G4 HIV-1/2 rapid test for VA, Department of Defence](https://medmira.com/press-release/medmira-inc-and-lovell-announce-partnership-to-increase-access-to-reveal-g4-hiv-1-2-rapid-test-for-va-department-of-defence/): Halifax, Nova Scotia, 17th of April, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) and Lovell® Government Services announced today that they have partnered to serve federal healthcare systems such as the Veterans Health Administration (VHA), the Military Health System (MHS), and the Indian Health Service (IHS). Lovell Government Services will serve as MedMira’s Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to serve these customers through federal contracting systems. 
- [MedMira Announces Partnership with MediGroup Physician Services in the United States](https://medmira.com/press-release/medmira-announces-partnership-with-medigroup-physician-services-in-the-united-states/): Halifax, Nova Scotia, 27th of February, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today its partnership with MediGroup, a leader in the US health care industry since 1999. This new partnership allows the Company to promote and sell its products to over 44,000 existing customers.
- [MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada](https://medmira.com/press-release/medmira-announces-exclusive-distribution-agreement-with-trimedic-inc-for-canada/): Halifax, Nova Scotia, 25th of February, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today its exclusive distribution agreement with Trimedic Inc. for the Canadian market. This partnership allows MedMira to expedite its growth in the Canadian market with the recently Health Canada approved Multiplo® TP/HIV rapid antibody test and its Reveal® G4 HIV-1/2 rapid antibody test. Both products have been granted Class 4 Medical Device Licenses, the highest regulatory classification for medical diagnostics in Canada.
- [MedMira Receives Investigational Testing Authorizations for Multiplo® TP/HIV Self-Test and Non-Professional Use Applications](https://medmira.com/press-release/medmira-receives-investigational-testing-authorizations-for-multiplo-tp-hiv-self-test-and-non-professional-use-applications/): Halifax, Nova Scotia, 21st of January, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received Investigational Testing Authorizations (ITAs) from Health Canada to begin clinical trials for new label claim applications of its recently Health Canada approved Multiplo® TP/HIV rapid test. These applications include use as a self-test and for non-professional administration, expanding access to testing for syphilis and HIV in Canada.
- [MedMira receives Health Canada approval for its Reveal® G4 Rapid HIV-1/2 Test for Point-of-Care use](https://medmira.com/press-release/medmira-receives-health-canada-approval-for-its-reveal-g4-rapid-hiv-1-2-test-for-point-of-care-use/): Halifax, Nova Scotia – January 14, 2025 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received today the approval from Health Canada for its Reveal® Rapid G4 HIV-1/2 Test (Reveal® HIV test) for Point-of-Care (POC) use. The Reveal® HIV rapid test has achieved a sensitivity of 99.64% and a specificity of 99.71% and with it is highly suitable for health care professionals who require a fast, reliable, and high-quality result to be used in any health care setting.
- [MedMira receives investigational testing authorization for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test](https://medmira.com/press-release/medmira-receives-investigational-testing-authorization-for-its-multiplo-complete-syphilis-tp-ntp-antibody-test/): Halifax, Nova Scotia,  9 January, 2025 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trials for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP), a cutting edge device that can determine active and non-active syphilis.
- [MedMira receives Health Canada approval for its Multiplo® Rapid (TP/HIV) Test for Syphilis and HIV](https://medmira.com/press-release/medmira-receives-health-canada-approval-for-its-multiplo-rapid-tp-hiv-test-for-syphilis-and-hiv-2/): Halifax, Nova Scotia - December 24, 2024 – MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received today, on December 24, 2024, the approval from Health Canada for its Multiplo® Rapid TP/HIV Test (Multiplo® TP/HIV) to be rolled out across Canada, a critical point-of-care tool to address the health crises with HIV and syphilis in Canada. The single Reveal® TP (Syphilis) approval will follow soon after this more complex approval.
- [Clinical Trials to get Underway with Multiplo® Complete Syphilis (TP/nTP) Antibody Test – A Potential Game Changer to Address Syphilis Health Crisis in Canada](https://medmira.com/press-release/medmira-receives-health-canada-approval-for-its-multiplo-rapid-tp-hiv-test-for-syphilis-and-hiv/): Halifax, Nova Scotia, 13 August, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces it will conduct full clinical trials for its unique Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP) with the goal of getting it licensed in Canada. The new Multiplo® TP/nTP will provide a complete system which combines screening and confirmation in one test. Just announced by Health Minister Mark Holland, the clinical trial is happening in partnership with REACH Nexus at St. Michael’s Hospital’s MAP Centre for Urban Health Solutions with funding from the Canadian Institute of Health Research (CIHR).
- [Miriad® MultiLinx™ – One Test, More Answers](https://medmira.com/news_events/miriad-multilinx-one-test-more-answers/): Introducing MedMira's latest product now available anywhere for Tissue and Eye Banks: Miriad MultiLinx: One Test, More Answers.
- [Innovation made easy](https://medmira.com/news_events/innovation-made-easy/): With MedMira's patented RVF Technology, there are a myriad of possibilities: As an example, our latest custom made product for one of our clients:
- [MedMira Receives Canadian Patent for its Unique Quantitative Diagnostic System](https://medmira.com/press-release/medmira-receives-canadian-patent-for-its-unique-quantitative-diagnostic-system/): Halifax, Nova Scotia, March 13, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a Canadian patent (number 2,949,634) for its new innovative and quantitative test system. This is in addition to the U.S. patent (number 11,353,450) received in 2022. Through this new patent, MedMira is to further diversify its patent portfolio and expand on its Rapid Vertical Flow Technology™ (RVF) based diagnostic tests. This is a step forward in empowering the Company’s strategic vision by offering a rapid multiplexed quantitative diagnostic system from screening to confirmation to monitoring disease progression. The synergies between both patented technologies allow MedMira to continue its corporate aim to provide the market with a highly effective and affordable alternative to the current costly and time-consuming screening and monitoring systems.
- [Corporate Update on Clinical Evaluation of MedMira’s Products](https://medmira.com/press-release/corporate-update-on-clinical-evaluation-of-medmiras-products/): Halifax, Nova Scotia,1 February, 2024 – Today, MedMira Inc. (MedMira) (TSXV: MIR) is pleased to provide an update on the ongoing review process by Health Canada. The Company made the submission and since then has been working with the regulator on the additional clarifications and at the same time has been working towards extending its intended use highlighting the increasing need in maternity screening.
- [U.S. FDA Approves MedMira’s Advanced Reveal® G4 Rapid HIV-1/2 Antibody Test](https://medmira.com/press-release/u-s-fda-approves-medmiras-advanced-reveal-g4-rapid-hiv-1-2-antibody-test/): Halifax, Nova Scotia, 13 December, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR). MedMira Inc. proudly announces today the successful attainment of 510(k) clearance for the HIV-2 claim on the Reveal® G4 Rapid HIV-1/2 antibody test in the United States. This achievement marks a significant milestone for MedMira, positioning the company as a key player in the HIV testing landscape and addressing the demand for comprehensive HIV screening mandated by various State laws across the nation.
- [FY2023 Update](https://medmira.com/press-release/fy2023-update/): Corporate UpdateThroughout the reporting period, the Company achieved significant milestones in its pursuit of FDA and Health Canada approvals for a range of products. A standout accomplishment is the progress made with MedMira’s 510(k) (FDA) approval for its Reveal G4 Rapid HIV-1/2 antibody test. MedMira has submitted a comprehensive study for the additional HIV-2 claim based on the Company’s completed study in the Ivory Coast. The study showed a sensitivity of 100% for HIV-1 and HIV-2. In addition, MedMira’s Reveal® G4 rapid HIV antibody test achieved a flawless 100% specificity and was reactive in early HIV-1 infections and seroconverts. In November 2023, MedMira received the feedback and with it the FDA acknowledged the successful substantive review completion. With this the Company will enter into the interactive review process to finalise any outstanding items such as labels and packaging inserts.
- [Update on MedMira’s Regulatory Path in Canada and the USA](https://medmira.com/press-release/update-on-medmiras-regulatory-path-in-canada-and-the-usa/): Halifax, Nova Scotia, 27 September, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its progress to achieve regulatory approval in Canada and the USA for its infectious disease rapid tests. Currently the Company has two submissions filed with Health Canada and one submission with the US FDA. In addition, the Company is in the process to complete its clinical trials and subsequently gather all necessary data for the final submission of its Reveal® TP (Syphilis) antibody test and its Reveal® G4 rapid HIV antibody test. Further updates will follow in the course of the next weeks.
- [MedMira receives 3 new trademarks](https://medmira.com/press-release/medmira-receives-3-new-trademarks/): MedMira has been notified that the Company has successfully defended its claim on its submitted trademarks.
- [Finger-Prick Test Developed For ‘Trich’ A Common, Undiagnosed STI](https://medmira.com/press-release/finger-prick-test-developed-for-trich-a-common-undiagnosed-sti/): Washington State University: Link to full article (WSU News)
- [Update on MedMira’s Reveal® TP (Syphilis) Clinical Trials in Canada](https://medmira.com/press-release/update-on-medmiras-reveal-tp-syphilis-clinical-trials-in-canada/): Halifax, Nova Scotia, 14 March, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its progress to achieve regulatory approval in Canada for its Reveal® TP (Syphilis) antibody test. The Company has successfully started its clinical trials in Saskatchewan in early March 2023 and commences another trial in British Colombia by the end of this month.
- [MedMira receives CE mark for its VYRA™ CoV2Flu Antigen Test](https://medmira.com/press-release/medmira-receives-ce-mark-for-its-vyra-cov2flu-antigen-test/): Halifax, Nova Scotia, 11 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of the CE mark for its VYRA™ CoV2Flu Antigen Test (VYRA™ CoV2Flu), the fastest combination antigen test available to detect SARS-CoV-2, Flu A and Flu B. The Company received the CE mark and VYRA™ CoV2Flu is now available in Europe and any countries accepting the CE mark.
- [MedMira’s G4 HIV (FDA approved) rapid test – an independent evaluation by the CDC](https://medmira.com/press-release/medmiras-g4-hiv-fda-approved-rapid-test-an-independent-evaluation-by-the-cdc-2/): Performance Evaluation of the MedMira Reveal G4 LAB S/P and POC HIV Antibody Rapid Screening Tests using Plasma and Whole Blood Specimens
- [Point-of-Care Diagnostic for Trichomonas vaginalis based on MedMira’s RVF Technology™](https://medmira.com/press-release/u-s-fda-approves-medmiras-advanced-reveal-g4-rapid-hiv-1-2-antibody-test-duplicate/): Halifax, Nova Scotia, 3 January, 2023 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the publication of Point-of-Care Diagnostic for Trichomonas vaginalis, the Most Prevalent, Non-Viral Sexually Transmitted Infection – (available: https://www.mdpi.com/2076-0817/12/1/77), in the special edition of Pathogens by MDPI, a Swiss based medical journal. The article written by Professor John Alderete from the School of Molecular Biosciences, Washington State University, outlines the successful development of a POC diagnostic device for Trichomonas vaginalis based on MedMira’s RVF Technology™.
- [MedMira Introduces VYRA TriDemic](https://medmira.com/press-release/medmira-introduces-vyra-tridemic/): Halifax, Nova Scotia, 29 December, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) presents its latest addition to the VYRA™ product line, the VYRA™ TriDemic Antigen Rapid Test for the simultaneous detection of SARS-CoV-2, Flu A, Flu B and Respiratory Syncytial Virus (RSV). VYRA™ TriDemic, a four-in-one test, which is a direct response to the rise of RSV cases globally.
- [MedMira’s Multiplo TP/HIV Rapid Test: One Test, More Answers](https://medmira.com/press-release/medmiras-multiplo-tp-hiv-rapid-test-one-test-more-answers/): A study completed by the Indian Red Cross Blood Society showed that MedMira's Multiplo® TP/HIV Rapid Test is your immediate quality answer.
- [Dr. Hermes Chan, CEO, Co-Founder and Co-Inventor receives Queen’s Jubilee Platinum Medal](https://medmira.com/news_events/dr-hermes-chan-ceo-co-founder-and-co-inventor-receives-queens-jubilee-platinum-medal/): Rafah DiCostanzo, MLA for Clayton Park West acknowledges outstanding constituents and has proposed Dr. Hermes Chan, CEO, Co-Founder and Co-Inventor to receive the Queen's Jubilee Platinum Medal for his essential work during the pandemic.
- [MedMira receives CE mark for its VYRA™ COVID-19 Antigen Test](https://medmira.com/press-release/medmira-receives-ce-mark-for-its-vyra-covid-19-antigen-test/): Halifax, Nova Scotia, 14 October, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of the CE mark for its VYRA™ COVID-19 Antigen Test (VYRA™ COVID-19), the fastest SARS-CoV-2 Antigen test available. The Company received the CE mark today and is now available in Europe and any countries accepting the CE mark.
- [MedMira provides Progress Update](https://medmira.com/press-release/medmira-provides-progress-update/): Halifax, Nova Scotia, 30 September, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Dr. Sam Ratnam as MedMira’s Director of Scientific & Regulatory Affairs and provides an update on its regulatory progress in the U.S. market.
- [MedMira announces the appointment of Dr. Sam Ratnam as Director of Scientific & Regulatory Affairs](https://medmira.com/press-release/medmira-announces-the-appointment-of-dr-sam-ratnam-as-director-of-scientific-regulatory-affairs/): The management and board is delighted to have Dr. Ratnam joining our growing team and support MedMira’s various regulatory applications. Dr. Ratnam brings over 40 years of experience in public health, regulatory affairs and has been the principal in a number of important regulations set forward by the health authorities such as the guidelines on Syphilis, Hepatitis C or HPV. His invaluable expertise and intrinsic knowledge of the regulatory and clinical trial framework in Canada and the United States, will provide the Company even further momentum to push forward in its current and future applications.
- [MedMira Receives US Trademark for its REVEALCOVID-19](https://medmira.com/press-release/medmira-receives-us-trademark-for-its-revealcovid-19/): MedMira is delighted to announce the receipt of the United States of America Trademark for its REVEALCOVID-19 brand. The Company has been successful in its argument to receive the registered trademark for its COVID-19 Antibody related product lines.
- [MedMira Receives Grant from John Hopkins for its Multiplex STD Saliva Test](https://medmira.com/press-release/medmira-receives-grant-from-john-hopkins-for-its-multiplex-std-saliva-test/): Halifax, Nova Scotia, 26 July, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) received the confirmation letter from the John Hopkins School of Medicine, Division of Infectious Diseases stating that MedMira’s proposal titled “RVF Technology Multiplex saliva test for Sexually Transmitted Diseases (STDs)” was selected by the panel of experts and awarded a development grant. The development focuses on an unique saliva-based rapid test which detects simultaneously multiple STDs in one single test with immediate results.
- [New development of gold nano-particles](https://medmira.com/press-release/new-development-of-gold-nano-particles/): MedMira is continuously developing more ways to expand on future potentials of its RVF Technology, if this is customer satisfaction, increase of output or supporting regulatory for additional claims.
- [Multiplo® Product Line – A Simple Solution in One](https://medmira.com/news_events/multiplo-product-line-a-simple-solution-in-one/): MedMira's unique Multiplo® Product Line:
- [MedMira Receives Patent for its Unique Quantitative Diagnostic System](https://medmira.com/press-release/medmira-receives-patent-for-its-unique-quantitative-diagnostic-system/): Halifax, Nova Scotia, June 6, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a U.S. patent (number 11,353,450) for their new innovative and quantitative test system. Through this new patent, MedMira is to further diversify its patent portfolio and expand on its Rapid Vertical Flow Technology™ (RVF) based diagnostic tests. This is a step forward in empowering the Company’s strategic vision by offering a rapid multiplexed quantitative diagnostic system from screening to confirmation to monitoring disease progression. The synergies between both patented technologies allow MedMira to continue its corporate aim to provide the market with a highly effective and affordable alternative to the current costly and time-consuming screening and monitoring systems.
- [Update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market](https://medmira.com/news_events/update-on-the-new-in-vitro-diagnostic-medical-devices-regulation-ivdr-in-the-european-market/): Halifax, Nova Scotia, 27 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its regulatory progress in Europe and any market accepting the CE mark. MedMira has received the CE mark for three products in 2022 and has four additional applications currently pending with the regulatory body. As of today, the Company has been informed that all applications have been accepted and will be forwarded to the Competent Authority for final CE marking. The Company anticipates the respective decisions and CE marks within the coming weeks.
- [VYRA™ Product Line Update](https://medmira.com/press-release/vyra-product-line-update/): Halifax, Nova Scotia, 20 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for Canada for its VYRA™ product line. On the 10th of May 2022, Health Canada issued to all stakeholder further information about the current Interim Order No. 3. As a result, the regulators have clearly defined the pathway to achieve the Interim Order and with it provided the Company with the last requirement to complete its final application for their review.
- [Test yourself in a smart way](https://medmira.com/news_events/test-yourself-in-a-smart-way/): A fact sheet for the importance of testing for both TP/nTP.
- [MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test](https://medmira.com/press-release/medmira-receives-ce-mark-for-multiplo-complete-syphilis-tp-ntp-antib/): Halifax, Nova Scotia, 12 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving the CE mark for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP). This approval allows the Company to further strengthen its product offering in all markets accepting the CE mark. By utilizing its unique RVF technology™, MedMira offers the only commercially available combined screening and confirmation test which takes less than 3 minutes (from sample collection to easy-to-read results) for syphilis.
- [MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada](https://medmira.com/press-release/medmira-receives-the-ce-mark-for-its-reveal-tp-syphilis-and-starts-clinical-trials-in-canada/): Halifax, Nova Scotia, 9 March, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) launches its Reveal® TP (Syphilis) product in Europe and gets clinical trial underway in Canada. The Company received the CE mark today and is now available in Europe and any countries accepting the CE mark. Furthermore, the Company continues their work on the Investigational Testing Application (ITA) for the planned clinical trial in Canada to start in the spring with the support and partnership of REACH Nexus (www.reachnexus.ca) at the MAP Centre for Urban Health Solutions (www.maphealth.ca), housed at St. Michael’s Hospital of Unity Health Toronto.
- [Corporate update](https://medmira.com/press-release/corporate-update/): In the second financial quarter of FY2022, MedMira continued its strategic plan to focus its own product portfolio on the two fastest growing disease segments in the IVD rapid test market. Furthermore, the Company continued its work with public and private partners to develop new potential tests based on its Rapid Vertical Flow (RVF) Technology™ platform.
- [MedMira Provides a Pre-Annual General Meeting Update](https://medmira.com/press-release/medmira-provides-a-pre-annual-general-meeting-update/): Halifax, Nova Scotia, 4 February, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) provides a pre-Annual General Meeting (AGM) update on its regulatory and product development progress. This includes its COVID-19 and its infectious disease products with the latest pre-submission for MedMira’s HCV Rapid Test to the FDA. This update serves the purpose to inform all shareholders of any potentially discussed topics during the physical AGM meeting held on this day.
- [MedMira’s COVID-19 Tests – for ANY STAGE](https://medmira.com/news_events/medmiras-covid-19-tests-for-any-stage/): Download the MedMira COVID-19 testing overview
- [Update on Validation of VYRA™ CoV2Flu](https://medmira.com/press-release/medmira-provides-a-pre-annual-general-meeting-update-duplicate/): By analyzing the mutation sites of N protein and their proportion according to the coronavirus sequences released by the GISAID database, full-length N protein recombinant antigens corresponding to VOC（Variants of Concern) and other mutant strains have been obtained as a mean to validate the current VYRA™ CoV2Flu antigen test’s sensitivity.
- [MDSAP Certification](https://medmira.com/press-release/mdsap-certification/): We are delighted to announce the receipt of the MDSAP certificate today. This highlights our firm and long lasting commitment to the highest quality standards.
- [MedMira Announces VYRA™ CoV2Flu and Additional Regulatory Opportunities](https://medmira.com/press-release/medmira-announces-vyra-cov2flu-and-additional-regulatory-opportunities/): Halifax, Nova Scotia, 21 December, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its VYRATMproduct line by launching its VYRA™ CoV2Flu Rapid Antigen Rapid Test (VYRA™ CoV2Flu). Based on MedMira’s proprietary technology, this 3-in-1 test is developed to distinguish between SARS-CoV-2 and Influenza A or B infections. Furthermore, the Company takes advantage of the latest regulatory development surrounding the US FDA De Novo/510(k) clearance processes by applying for its COVID-19 products.
- [MedMira strengthen its Board with New Appointment](https://medmira.com/press-release/medmira-strengthen-its-board-with-new-appointment/): Halifax, Nova Scotia, 17 December 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announced today the appointment of Mr. Thomas Bergmann to the board effective immediately.
- [MedMira announces significant debt reduction and additional growth capital](https://medmira.com/press-release/medmira-announces-significant-debt-reduction-and-additional-growth-capital/): Halifax, Nova Scotia, 14 December, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces a financial package of over $5.23 million to support the Company’s FY2022 corporate strategy by its largest shareholder and related parties. As part of the deal, MedMira receives a cash injection of $1.67 million and a reduction of $3.56 million of the Company’s current liabilities in exchange for equity.
- [Performance Update on World Health Organisation SARS-CoV2 Serology Standards](https://medmira.com/press-release/performance-update-on-world-health-organisation-sars-cov2-serology-standards/): Halifax, Nova Scotia, 14 June, 2021 – MedMira Inc. (MedMira) (TSXV: MIR) announces the World Health Organization (WHO) SARS-CoV-2 serology standards testing results. The REVEALCOVID-19™ PLUS Total Antibody and the REVEALCOVID-19™ Nab-Y Competitive Neutralizing Antibody Test have achieved a 100% agreement.
- [Product and Regulatory Update on MedMira’s COVID-19 Product Family](https://medmira.com/press-release/product-and-regulatory-update-on-medmiras-covid-19-product-family/): Halifax, Nova Scotia, 03 March, 2021 – MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its product portfolio and outlines the company’s COVID-19 market and regulatory plan.
- [Progress Update on MedMira’s COVID-19 Product Family](https://medmira.com/press-release/progress-update-on-medmiras-covid-19-product-family/): Halifax, Nova Scotia, 29 January, 2021 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the development of a rapid antibody test prototype that detects the presence of the neutralizing antibodies against the SARS-CoV-2 virus. These antibodies bind to the specific parts of the virus, decreasing the viral infectivity and potentially protecting the patient from the severe COVID-19 symptom presentation or future SARS-CoV-2 reinfection. Not all antibodies can block the virus from infecting the patient, and, according to the recent reports, the levels of neutralizing antibodies vary, so as the potency of the antibody protection. Once extensively validated, MedMira’s neutralizing antibody test can effectively pinpoint the antibodies with the blocking capability, potentially, serving as a powerful tool for the qualitative assessment of the antibody status pre- and post-vaccination, as well as providing insights into one’s immunity to SARS-CoV-2. At this time, there is no guarantee that this product will meet all regulatory requirements and receive a subsequent regulatory approval.

## Pages
- [Clinical Evidence / Publications](https://medmira.com/clinical-evidence-publications/): Explore clinical studies and publications on MedMira’s technologies.
- [Partner Solution](https://medmira.com/partner-solution/): Rapid diagnostic solutions, developed and brought to market in partnership.
- [Contact](https://medmira.com/contact/): Your central point of contact for MedMira inquiries and information
- [News](https://medmira.com/news/): Latest company updates, announcements, and upcoming events from MedMira.
- [Careers](https://medmira.com/careers/): Do meaningful work every day and help provide answers when they matter most.
- [About us](https://medmira.com/about-us/): We are an innovation-driven company on a mission to transform healthcare through rapid testing that save time, reduce costs empower decisions, and improve lives.
- [Partners](https://medmira.com/partners/): We select the best global partners to offer world-class access to reliable rapid testing.
- [Press Release](https://medmira.com/press-release/): Press Release
- [Corporate Governance](https://medmira.com/corporate-governance/): MedMira is committed to creating lasting value for all stakeholders. Our Corporate Governance principles provide the foundation for this commitment by guiding our business activities toward sustainable value creation and continuous innovation. They also define a management culture that aligns with recognised standards of good corporate governance and ensures transparent, reliable communication.
- [Financials](https://medmira.com/financials/): Financials & Filings
- [Overview](https://medmira.com/overview/): Investors Overview
- [Catalog](https://medmira.com/catalog/): Explore our comprehensive portfolio of rapid tests, from single-analyte to multiplex panels across various applications.
- [Miriad](https://medmira.com/miriad/): mir iad®
- [Roadmap](https://medmira.com/roadmap/): Driven by technology and guided by clinical needs, we advance rapid testing with purpose.This roadmap outlines the developments shaping our next generation of solutions.
- [MEDDUO](https://medmira.com/rvf-technology/medduo/): med duoTM
- [MiROQ](https://medmira.com/miroq/): Discover the next generation of highly sensitive, quantitative liquid biopsy - for fast screening, supporting diagnostic accuracy, and continuous monitoring.
- [RVF Technology](https://medmira.com/rvf-technology/): MedMira Rapid Vertical Flow Technology™
- [Home](https://medmira.com/): Our rapid tests are validated by rigorous clinical studies and regulatory approvals, achieving industry-leading results. With a high sensitivity rate, our solutions are trusted by healthcare professionals worldwide, delivering unparalleled accuracy when precision matters most.

## Products
- [HIV-1/2](https://medmira.com/product/hiv-1-2/): Accurate, rapid detection of HIV antibodies in whole blood, plasma, or serum - trusted worldwide for reliable diagnosis in just three simple steps.
- [RVF Toolkit](https://medmira.com/product/rvf-toolkit/): mir iad®
- [TP/HIV/HCV](https://medmira.com/product/tp-hiv-hcv/): multi plo®
- [HBc/HIV/HCV](https://medmira.com/product/hbc-hiv-hcv/): multi plo®
- [HCV/HIV](https://medmira.com/product/hcv-hiv/): multi plo®
- [TP/HIV](https://medmira.com/product/tp-hiv/): multi plo® Rapid Test
- [Complete Syphilis (TP/nTP)](https://medmira.com/product/complete-syphilis-tp-ntp/): multi plo®
- [TP](https://medmira.com/product/tp/): Accurate, rapid detection of Syphilis antibodies in whole blood - trusted worldwide for reliable diagnosis in just three simple steps.
- [HCV](https://medmira.com/product/hcv/): Accurate, rapid detection of Hepatitis C antibodies in whole blood, plasma, or serum in just three simple steps.

## Publications
- [Evaluating the MedMira Multiplo® Complete Syphilis (TP/nTP) antibody test in a sexually transmitted infection clinic in Ottawa, Canada: increased rapid diagnosis and improved antibiotic stewardship.](https://medmira.com/publication/evaluating-the-medmira-multiplo-complete-syphilis-tp-ntp-antibody-test-in-a-sexually-transmitted-infection-clinic-in-ottawa-canada-increased-rapid-diagnosis-and-improved-antibiotic-stewardsh/)
- [Feasibility, Preference, and Impact of a Rapid Multiplexed Point-of-Care Digital Innovation (AideSmart!) to Expedite Screening of Sexually Transmitted Blood-Borne Infections in At-Risk Populations in Canada: Cross-Sectional Study](https://medmira.com/publication/feasibility-preference-and-impact-of-a-rapid-multiplexed-point-of-care-digital-innovation-aidesmart-to-expedite-screening-of-sexually-transmitted-blood-borne-infections-in-at-risk-populations-in/)
- [Sensitivity and specificity of two investigational Point-of-Care tests for Syphilis and HIV (PoSH Study) for the diagnosis and treatment of infectious syphilis in Canada: a cross-sectional study](https://medmira.com/publication/sensitivity-and-specificity-of-two-investigational-point-of-care-tests-for-syphilis-and-hiv-posh-study-for-the-diagnosis-and-treatment-of-infectious-syphilis-in-canada-a-cross-sectional-study/)
- [Point-of-Care Diagnostic for Trichomonas vaginalis, the Most Prevalent, Non-Viral Sexually Transmitted Infection](https://medmira.com/publication/point-of-care-diagnostic-for-trichomonas-vaginalis-the-most-prevalent-non-viral-sexually-transmitted-infection/)
- [Performance evaluation of the MedMira reveal G4 LAB S/P and POC HIV antibody rapid screening tests using plasma and whole blood specimens](https://medmira.com/publication/performance-evaluation-of-the-medmira-reveal-g4-lab-s-p-and-poc-hiv-antibody-rapid-screening-tests-using-plasma-and-whole-blood-specimens/)
- [Development of a SERS-Based Rapid Vertical Flow Assay for Point-of-Care Diagnostics](https://medmira.com/publication/development-of-a-sers-based-rapid-vertical-flow-assay-for-point-of-care-diagnostics/)
- [Field Evaluation of a Dual Rapid Immunodiagnostic Test for HIV and Syphilis Infection in Peru](https://medmira.com/publication/field-evaluation-of-a-dual-rapid-immunodiagnostic-test-for-hiv-and-syphilis-infection-in-peru/)
- [Comparison of Rapid Point-of-Care Tests for Detection of Antibodies to Hepatitis C Virus](https://medmira.com/publication/comparison-of-rapid-point-of-care-tests-for-detection-of-antibodies-to-hepatitis-c-virus/)
- [Laboratory evaluation of three dual rapid diagnostic tests for HIV and syphilis in China and Nigeria](https://medmira.com/publication/laboratory-evaluation-of-three-dual-rapid-diagnostic-tests-for-hiv-and-syphilis-in-china-and-nigeria/)
- [Use of rapid HIV assays as supplemental tests in specimens with repeatedly reactive screening immunoassay results not confirmed by HIV-1 Western blot](https://medmira.com/publication/use-of-rapid-hiv-assays-as-supplemental-tests-in-specimens-with-repeatedly-reactive-screening-immunoassay-results-not-confirmed-by-hiv-1-western-blot/)
- [Rapid diagnostic HCV antibody assays](https://medmira.com/publication/rapid-diagnostic-hcv-antibody-assays/)
- [Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA](https://medmira.com/publication/field-based-performance-of-three-pre-market-rapid-hepatitis-c-virus-antibody-assays-in-stahr-study-to-assess-hepatitis-c-risk-among-young-adults-who-inject-drugs-in-san-diego-ca/)
- [Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus](https://medmira.com/publication/evaluation-of-three-rapid-screening-assays-for-detection-of-antibodies-to-hepatitis-c-virus/)
- [Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites](https://medmira.com/publication/performance-of-premarket-rapid-hepatitis-c-virus-antibody-assays-in-4-national-human-immunodeficiency-virus-behavioral-surveillance-system-sites/)
- [HIV seroprevalence and associated risk factors among male inmates at the Belize Central Prison](https://medmira.com/publication/hiv-seroprevalence-and-associated-risk-factors-among-male-inmates-at-the-belize-central-prison/)
- [Rapid HIV test kits](https://medmira.com/publication/rapid-hiv-test-kits/)
- [Accuracy of office-based immunoassays for the diagnosis of Helicobacter pylori infection in children](https://medmira.com/publication/accuracy-of-office-based-immunoassays-for-the-diagnosis-of-helicobacter-pylori-infection-in-children/)
- [Rapid method for the detection of anti-HCV antibodies in patients with chronic hepatitis C](https://medmira.com/publication/rapid-method-for-the-detection-of-anti-hcv-antibodies-in-patients-with-chronic-hepatitis-c/)

## Listing Items/Components
- [Results Mobile](https://medmira.com/?jet-engine=results-mobile): Page
- [Publications](https://medmira.com/?jet-engine=publications): -
- [Tags](https://medmira.com/?jet-engine=tags): Early detection
- [Search results](https://medmira.com/?jet-engine=search-results): Page
- [Jobs](https://medmira.com/?jet-engine=jobs): Function: Job ID: View Details
- [Catalog items](https://medmira.com/?jet-engine=catalog-items): Regulatory status
- [Tests](https://medmira.com/?jet-engine=tests): Miriad® POU+ Format LAB+ Format
- [Products](https://medmira.com/?jet-engine=products): The MiROQ™ System Upcoming solutions expanding our portfolio